Health
New STRENGTH Analysis Reignites Debate on Omega-3 CV Benefits – Medscape
The new analysis showing no benefits linked to higher achieved levels of EPA casts doubt over the use of high-dose omega-3 fatty acid products for preventing cardiovascular…
Questions over the cardiovascular benefits shown in the REDUCE-IT trial with icosapent ethyl, a high-dose eicosapentaenoic acid (EPA) product, have been reignited with a new analysis from the STRENGTH trial showing no benefit of a high-dose combined omega-3 fatty acid product in patients who achieved the highest EPA levels and no harm in those with the highest levels of docosahexaenoic acid (DHA).
STRENGTH investigator Steven Nissen, MD, said these new results add to concerns about the positive…
-
Noosa News24 hours agoAfter Hours Gallery Visits, French Dining and Garden Illuminations: Your Guide to the Ultimate Melbourne Culture Fix
-
General21 hours agoDeath of 86-year-old driver in Karoonda Highway crash prompts push for change
-
General17 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
Business17 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?